Selected research
Industry Research
Systemic Antifungals Industry Research Report 2026
Market perspective
The global Systemic Antifungals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Systemic Antifungals market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Systemic Antifungals market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Systemic Antifungals market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Systemic Antifungals include MSD, Zhuhai Ebang Pharmaceutical, Chiatai Tianqing, Xian-janssen, Novartis, Merck, Livzon Group Livzon Pharmaceutical Factory, Honz Pharmaceutical and Pfizer, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Systemic Antifungals market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Systemic Antifungals.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Systemic Antifungals Market by Company
MSD
Zhuhai Ebang Pharmaceutical
Chiatai Tianqing
Xian-janssen
Novartis
Merck
Livzon Group Livzon Pharmaceutical Factory
Honz Pharmaceutical
Pfizer
CR Pharma
Haisco Pharmaceutical
Medisan
Chengdu Brilliant Pharmaceutical
Bayer
Liposome Company
Gilead Sciences
Astellas Pharma
Systemic Antifungals Segment by Type
Injections
Oral
Systemic Antifungals Segment by Application
Clinic
Hospital
Drugstores
Others
Systemic Antifungals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Antifungals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Systemic Antifungals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Antifungals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Systemic Antifungals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injections
- Oral
Applications
- Clinic
- Hospital
- Drugstores
- Others
Companies covered
- MSD
- Zhuhai Ebang Pharmaceutical
- Chiatai Tianqing
- Xian-janssen
- Novartis
- Merck
- Livzon Group Livzon Pharmaceutical Factory
- Honz Pharmaceutical
- Pfizer
- CR Pharma
- Haisco Pharmaceutical
- Medisan
- Chengdu Brilliant Pharmaceutical
- Bayer
- Liposome Company
- Gilead Sciences
- Astellas Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Systemic Antifungals by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Injections
- 2.2.3 Oral
- 2.3 Systemic Antifungals by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Drugstores
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Systemic Antifungals Breakdown Data by Type
- 3.1 Global Systemic Antifungals Historic Market Size by Type (2021-2026)
- 3.2 Global Systemic Antifungals Forecasted Market Size by Type (2027-2032)
4 Systemic Antifungals Breakdown Data by Application
- 4.1 Global Systemic Antifungals Historic Market Size by Application (2021-2026)
- 4.2 Global Systemic Antifungals Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Systemic Antifungals Market Perspective (2021-2032)
- 5.2 Global Systemic Antifungals Growth Trends by Region
- 5.2.1 Global Systemic Antifungals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Systemic Antifungals Historic Market Size by Region (2021-2026)
- 5.2.3 Systemic Antifungals Forecasted Market Size by Region (2027-2032)
- 5.3 Systemic Antifungals Market Dynamics
- 5.3.1 Systemic Antifungals Industry Trends
- 5.3.2 Systemic Antifungals Market Drivers
- 5.3.3 Systemic Antifungals Market Challenges
- 5.3.4 Systemic Antifungals Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Systemic Antifungals Players by Revenue
- 6.1.1 Global Top Systemic Antifungals Players by Revenue (2021-2026)
- 6.1.2 Global Systemic Antifungals Revenue Market Share by Players (2021-2026)
- 6.2 Global Systemic Antifungals Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Systemic Antifungals Head Office and Area Served
- 6.4 Global Systemic Antifungals Players, Product Type & Application
- 6.5 Global Systemic Antifungals Manufacturers Established Date
- 6.6 Global Systemic Antifungals Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Systemic Antifungals Market Size (2021-2032)
- 7.2 North America Systemic Antifungals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Systemic Antifungals Market Size by Country (2021-2026)
- 7.4 North America Systemic Antifungals Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Systemic Antifungals Market Size (2021-2032)
- 8.2 Europe Systemic Antifungals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Systemic Antifungals Market Size by Country (2021-2026)
- 8.4 Europe Systemic Antifungals Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Systemic Antifungals Market Size (2021-2032)
- 9.2 Asia-Pacific Systemic Antifungals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Systemic Antifungals Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Systemic Antifungals Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Systemic Antifungals Market Size (2021-2032)
- 10.2 South America Systemic Antifungals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Systemic Antifungals Market Size by Country (2021-2026)
- 10.4 South America Systemic Antifungals Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Systemic Antifungals Market Size (2021-2032)
- 11.2 Middle East & Africa Systemic Antifungals Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Systemic Antifungals Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Systemic Antifungals Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 MSD
- 12.1.1 MSD Company Information
- 12.1.2 MSD Business Overview
- 12.1.3 MSD Revenue in Systemic Antifungals Business (2021-2026)
- 12.1.4 MSD Systemic Antifungals Product Portfolio
- 12.1.5 MSD Recent Developments
- 12.2 Zhuhai Ebang Pharmaceutical
- 12.2.1 Zhuhai Ebang Pharmaceutical Company Information
- 12.2.2 Zhuhai Ebang Pharmaceutical Business Overview
- 12.2.3 Zhuhai Ebang Pharmaceutical Revenue in Systemic Antifungals Business (2021-2026)
- 12.2.4 Zhuhai Ebang Pharmaceutical Systemic Antifungals Product Portfolio
- 12.2.5 Zhuhai Ebang Pharmaceutical Recent Developments
- 12.3 Chiatai Tianqing
- 12.3.1 Chiatai Tianqing Company Information
- 12.3.2 Chiatai Tianqing Business Overview
- 12.3.3 Chiatai Tianqing Revenue in Systemic Antifungals Business (2021-2026)
- 12.3.4 Chiatai Tianqing Systemic Antifungals Product Portfolio
- 12.3.5 Chiatai Tianqing Recent Developments
- 12.4 Xian-janssen
- 12.4.1 Xian-janssen Company Information
- 12.4.2 Xian-janssen Business Overview
- 12.4.3 Xian-janssen Revenue in Systemic Antifungals Business (2021-2026)
- 12.4.4 Xian-janssen Systemic Antifungals Product Portfolio
- 12.4.5 Xian-janssen Recent Developments
- 12.5 Novartis
- 12.5.1 Novartis Company Information
- 12.5.2 Novartis Business Overview
- 12.5.3 Novartis Revenue in Systemic Antifungals Business (2021-2026)
- 12.5.4 Novartis Systemic Antifungals Product Portfolio
- 12.5.5 Novartis Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Systemic Antifungals Business (2021-2026)
- 12.6.4 Merck Systemic Antifungals Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 Livzon Group Livzon Pharmaceutical Factory
- 12.7.1 Livzon Group Livzon Pharmaceutical Factory Company Information
- 12.7.2 Livzon Group Livzon Pharmaceutical Factory Business Overview
- 12.7.3 Livzon Group Livzon Pharmaceutical Factory Revenue in Systemic Antifungals Business (2021-2026)
- 12.7.4 Livzon Group Livzon Pharmaceutical Factory Systemic Antifungals Product Portfolio
- 12.7.5 Livzon Group Livzon Pharmaceutical Factory Recent Developments
- 12.8 Honz Pharmaceutical
- 12.8.1 Honz Pharmaceutical Company Information
- 12.8.2 Honz Pharmaceutical Business Overview
- 12.8.3 Honz Pharmaceutical Revenue in Systemic Antifungals Business (2021-2026)
- 12.8.4 Honz Pharmaceutical Systemic Antifungals Product Portfolio
- 12.8.5 Honz Pharmaceutical Recent Developments
- 12.9 Pfizer
- 12.9.1 Pfizer Company Information
- 12.9.2 Pfizer Business Overview
- 12.9.3 Pfizer Revenue in Systemic Antifungals Business (2021-2026)
- 12.9.4 Pfizer Systemic Antifungals Product Portfolio
- 12.9.5 Pfizer Recent Developments
- 12.10 CR Pharma
- 12.10.1 CR Pharma Company Information
- 12.10.2 CR Pharma Business Overview
- 12.10.3 CR Pharma Revenue in Systemic Antifungals Business (2021-2026)
- 12.10.4 CR Pharma Systemic Antifungals Product Portfolio
- 12.10.5 CR Pharma Recent Developments
- 12.11 Haisco Pharmaceutical
- 12.11.1 Haisco Pharmaceutical Company Information
- 12.11.2 Haisco Pharmaceutical Business Overview
- 12.11.3 Haisco Pharmaceutical Revenue in Systemic Antifungals Business (2021-2026)
- 12.11.4 Haisco Pharmaceutical Systemic Antifungals Product Portfolio
- 12.11.5 Haisco Pharmaceutical Recent Developments
- 12.12 Medisan
- 12.12.1 Medisan Company Information
- 12.12.2 Medisan Business Overview
- 12.12.3 Medisan Revenue in Systemic Antifungals Business (2021-2026)
- 12.12.4 Medisan Systemic Antifungals Product Portfolio
- 12.12.5 Medisan Recent Developments
- 12.13 Chengdu Brilliant Pharmaceutical
- 12.13.1 Chengdu Brilliant Pharmaceutical Company Information
- 12.13.2 Chengdu Brilliant Pharmaceutical Business Overview
- 12.13.3 Chengdu Brilliant Pharmaceutical Revenue in Systemic Antifungals Business (2021-2026)
- 12.13.4 Chengdu Brilliant Pharmaceutical Systemic Antifungals Product Portfolio
- 12.13.5 Chengdu Brilliant Pharmaceutical Recent Developments
- 12.14 Bayer
- 12.14.1 Bayer Company Information
- 12.14.2 Bayer Business Overview
- 12.14.3 Bayer Revenue in Systemic Antifungals Business (2021-2026)
- 12.14.4 Bayer Systemic Antifungals Product Portfolio
- 12.14.5 Bayer Recent Developments
- 12.15 Liposome Company
- 12.15.1 Liposome Company Company Information
- 12.15.2 Liposome Company Business Overview
- 12.15.3 Liposome Company Revenue in Systemic Antifungals Business (2021-2026)
- 12.15.4 Liposome Company Systemic Antifungals Product Portfolio
- 12.15.5 Liposome Company Recent Developments
- 12.16 Gilead Sciences
- 12.16.1 Gilead Sciences Company Information
- 12.16.2 Gilead Sciences Business Overview
- 12.16.3 Gilead Sciences Revenue in Systemic Antifungals Business (2021-2026)
- 12.16.4 Gilead Sciences Systemic Antifungals Product Portfolio
- 12.16.5 Gilead Sciences Recent Developments
- 12.17 Astellas Pharma
- 12.17.1 Astellas Pharma Company Information
- 12.17.2 Astellas Pharma Business Overview
- 12.17.3 Astellas Pharma Revenue in Systemic Antifungals Business (2021-2026)
- 12.17.4 Astellas Pharma Systemic Antifungals Product Portfolio
- 12.17.5 Astellas Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst